ReviewDeutsches Arzteblatt international2018
Molecular Imaging in Oncology Using Positron Emission Tomography.
Review in Deutsches Arzteblatt international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Development of Pd-Loaded Hf-Based Metal-Organic Framework as a Dual-Modal Contrast Agent for Photoacoustic Imaging and Computed Tomography.ACS biomaterials science & engineering · 2025Article
- Hypoxia Imaging in Lung Cancer: A PET-Based Narrative Review for Clinicians and Researchers.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Liquid Biopsy for Medical Imaging Analysis in Cancer Diagnosis.Current pharmaceutical design · 2025Review
- Iodinated PSMA Ligands as XFI Tracers for Targeted Cell Imaging and Characterization of Nanoparticles.International journal of molecular sciences · 2024Article
- Application and Performance of Artificial Intelligence (AI) in Oral Cancer Diagnosis and Prediction Using Histopathological Images: A Systematic Review.Biomedicines · 2023Review
- The Clinical Significance of Incidental GIT Uptake on PET/CT: Radiologic, Endoscopic, and Pathologic Correlation.Diagnostics (Basel, Switzerland) · 2023Article
- Recent Advances in Cardiovascular Diseases Research Using Animal Models and PET Radioisotope Tracers.International journal of molecular sciences · 2022Review
- Current Status ofDiagnostics (Basel, Switzerland) · 2022Review
- The Exception That Proves the Rule: How Sodium Chelation Can Alter the Charge-Cell Binding Correlation of Fluorescein-Based Multimodal Imaging Agents.ChemMedChem · 2022Article
- Oral Cancer Screening by Artificial Intelligence-Oriented Interpretation of Optical Coherence Tomography Images.Radiology research and practice · 2022Review
- Radiolabeling of functional oligonucleotides for molecular imaging.Frontiers in bioengineering and biotechnology · 2022Review
- Synthesis, Characterization and In Vitro Evaluation of Hybrid Monomeric Peptides Suited for Multimodal Imaging by PET/OI: Extending the Concept of Charge-Cell Binding Correlation.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Molecular Imaging of Inflammatory Disease.Biomedicines · 2021Review
- Metal-Organic Frameworks and Their Composites Towards Biomedical Applications.Frontiers in molecular biosciences · 2021Review
- [What does the nonradiologist expect from the radiologist?]Der Radiologe · 2020Review
- [Theranostics and hybrid imaging for somatostatin receptor-expressing tumors].Der Radiologe · 2020Review
- Dual Imaging Gold Nanoplatforms for Targeted Radiotheranostics.Materials (Basel, Switzerland) · 2020Article
- Radiolabeling of Nucleic Acid Aptamers for Highly Sensitive Disease-Specific Molecular Imaging.Pharmaceuticals (Basel, Switzerland) · 2018Review
- In Reply.Deutsches Arzteblatt international · 2018Article
- Some Necessary Additional Points.Deutsches Arzteblatt international · 2018Article
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnatomical and molecular data can be acquired simultaneously through the use of positron emission tomography (PET) in combination with computed tomography (CT) or magnetic resonance imaging (MRI) as a hybrid technique. A variety of radiopharmaceuticals can be used to characterize various metabolic processes or to visualize the expression of receptors, enzymes, and other molecular target structures.
methodsThis review is based on pertinent publications retrieved by a selective search in PubMed, as well as on guidelines from Germany and abroad and on systematic reviews and meta-analyses.
resultsEstablished radiopharmaceuticals for PET, such as 2-[18F]fluoro-2- deoxyglucose ([18F]FDG), enable the visualization of physiological processes on the molecular level and can provide vital information for clinical decision-making. For example, PET can be used to evaluate pulmonary nodules for malignancy with 95% sensitivity and 82% specificity. It can be used both for initial staging and for the guidance of further treatment. Alongside the PET radiopharmaceuticals that have already been well studied and evaluated, newer ones are increasingly becoming available for the noninvasive phenotyping of tumor diseases, e.g., for analyzing the expression of prostate-specific membrane antigen (PSMA), of somatostatin receptors, or of chemokine receptors on tumor cells.
conclusionPET is an important component of diagnostic algorithms in oncology. It can help make diagnosis more precise and treatment more individualized. An increasing number of PET radiopharmaceuticals are now expanding the available options for imaging. Many radiopharmaceuticals can be used not only for noninvasive analysis of the expression of therapeutically relevant target structures, but also for the ensuing, target-directed treatment with radionuclides.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.